Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 14/20 | 0.45 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687198 | 0.89 | MEN1 (0.50) | SMN1; SMN2MEN1HTTKMT2AABL1 | |
| SCHEMBL23091742 | 0.89 | MEN1 (0.50) | SMN1; SMN2MEN1HTTKMT2AABL1 | |
| SCHEMBL29687786 | 0.84 | MAPT (0.46) | MAPTABL1 | |
| SCHEMBL23091767 | 0.84 | MAPT (0.46) | MAPTABL1 | |
| SCHEMBL29687311 | 0.84 | RAB9A (0.52) | SMN1; SMN2MEN1HTTKMT2AMAPT | |
| SCHEMBL23091738 | 0.84 | RAB9A (0.52) | SMN1; SMN2MEN1HTTKMT2AMAPT | |
| SCHEMBL29687726 | 0.83 | ABL1 (0.47) | ABL1 | |
| SCHEMBL23091708 | 0.83 | TRPV1 (0.47) | SMN1; SMN2HTTMAPTRAB9ANPC1 | |
| SCHEMBL23091778 | 0.83 | ABL1 (0.48) | SMN1; SMN2MAPTRAB9AABL1 | |
| SCHEMBL29687484 | 0.83 | ABL1 (0.48) | SMN1; SMN2MAPTRAB9AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | claimed |
| CN-114502544-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2021048567-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2021-03-18 | — | — | WO | claimed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| CN-114502544-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021048567-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | SMN1; SMN2 2246/4885MEN1 2728/4885HTT 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.